Posted inComunicati
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE The only known investigational therapy for SBMA in Phase 3…
diretta News